AveXis, Inc. (AVXS) Insider Sells $1,518,450.00 in Stock
AveXis, Inc. (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $101.23, for a total value of $1,518,450.00. Following the transaction, the insider now directly owns 1,841,019 shares of the company’s stock, valued at $186,366,353.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of AveXis, Inc. (NASDAQ AVXS) traded up $4.61 during midday trading on Friday, hitting $104.53. The stock had a trading volume of 321,612 shares, compared to its average volume of 323,659.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same period in the previous year, the firm posted ($0.68) earnings per share. analysts expect that AveXis, Inc. will post -5.55 EPS for the current fiscal year.
WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/03/avexis-inc-avxs-insider-sells-1518450-00-in-stock.html.
A number of brokerages have issued reports on AVXS. Royal Bank Of Canada restated a “hold” rating and set a $92.00 price objective on shares of AveXis in a research report on Thursday. Canaccord Genuity began coverage on AveXis in a research report on Thursday, October 26th. They set a “hold” rating and a $110.00 price objective on the stock. Zacks Investment Research downgraded AveXis from a “buy” rating to a “hold” rating in a research report on Monday. Sanford C. Bernstein began coverage on AveXis in a research report on Thursday, July 27th. They set an “outperform” rating and a $108.00 price objective on the stock. Finally, Citigroup Inc. upped their price objective on AveXis from $100.00 to $116.00 and gave the company a “buy” rating in a research report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company’s stock. AveXis presently has a consensus rating of “Buy” and an average price target of $107.78.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors raised its holdings in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock worth $262,000 after buying an additional 284 shares during the period. Parametric Portfolio Associates LLC increased its holdings in AveXis by 2.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after purchasing an additional 598 shares during the period. American International Group Inc. increased its holdings in AveXis by 26.7% during the 1st quarter. American International Group Inc. now owns 3,521 shares of the company’s stock worth $268,000 after purchasing an additional 742 shares during the period. Seven Bridges Advisors LLC increased its holdings in AveXis by 49.4% during the 2nd quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock worth $210,000 after purchasing an additional 846 shares during the period. Finally, Jennison Associates LLC increased its holdings in AveXis by 0.5% during the 2nd quarter. Jennison Associates LLC now owns 184,668 shares of the company’s stock worth $15,172,000 after purchasing an additional 882 shares during the period. Hedge funds and other institutional investors own 94.71% of the company’s stock.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.